González-Llorente Nieves, Del Olmo-Benito Isabel, Muñoz-Ollero Natalia, Descalzo Miguel Angel, García-Doval Ignacio, Torrelo Antonio
Department of Learning & Speech-Language Pathology, Hospital del Niño Jesús, Madrid, Spain.
Research Unit, Fundación Academia Española de Dermatología y Venereología, Madrid, Spain.
Pediatr Dermatol. 2017 Sep;34(5):554-558. doi: 10.1111/pde.13229. Epub 2017 Aug 14.
Oral propranolol is considered the first choice for the treatment of infantile hemangiomas (IHs). There is a concern that administering propranolol in newborns and infants could induce adverse effects in learning and memory processes in the long term. The purpose of this study was to assess cognitive and memory functions in children who had been treated with propranolol for IH during their infancy.
A total of 23 children between 5 and 7.5 years of age who had been treated with oral propranolol for IH during infancy were tested for cognitive functions with the Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV) test and for memory functions with the Test of Memory and Learning (TOMAL).
Comparison of our sample with a normal distribution by a Shapiro-Wilk W test showed no significant difference for any of the composite scores in the WPPSI-IV and TOMAL tests except for positive asymmetry and concentration of scores around average (p = 0.01) in the WPPSI-IV composite score (mean intelligence), due to one atypically high score.
The distribution of scores for intelligence and memory scales in our study population was similar to that in the reference general population. These results fail to support any significant disturbance in intelligence and memory development in children treated during infancy with propranolol for IH.
口服普萘洛尔被认为是治疗婴儿血管瘤（IHs）的首选药物。有人担心在新生儿和婴儿中使用普萘洛尔可能会长期对学习和记忆过程产生不良影响。本研究的目的是评估婴儿期接受普萘洛尔治疗IH的儿童的认知和记忆功能。
共有23名5至7.5岁的儿童，他们在婴儿期曾接受口服普萘洛尔治疗IH，使用韦氏学前及初小儿童智力测验第四版（WPPSI-IV）测试认知功能，并使用记忆与学习测验（TOMAL）测试记忆功能。
通过Shapiro-Wilk W检验将我们的样本与正态分布进行比较，结果显示，除了WPPSI-IV综合得分（平均智力）中的正向不对称和分数集中在平均值附近（p = 0.01）外，WPPSI-IV和TOMAL测试中的任何综合得分均无显著差异，这是由于一个异常高的分数所致。
我们研究人群中智力和记忆量表的得分分布与参考一般人群相似。这些结果不支持婴儿期接受普萘洛尔治疗IH的儿童在智力和记忆发育方面存在任何显著障碍。
